You are here

The biomarker technologies market accounted for $21,594 million in 2018, and is expected to reach $58,508 million by 2026, registering a CAGR of 13.2% from 2019 to 2026

NEW YORK, Nov. 4, 2019 /PRNewswire/ --

Biomarker Technologies Market by Product (Consumables, and Instruments), Technology (Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Immunoassay, and Others), and Application (Drug Discovery, Diagnostics, and Personalized Medicine), and Indication (Cancer, Infectious Diseases, Autoimmune Disorders, Cardiovascular Disorders, and Others): Global Opportunity Analysis and Industry Forecast, 2019–2026

Read the full report:

The biomarker technologies market accounted for $21,594 million in 2018, and is expected to reach $58,508 million by 2026, registering a CAGR of 13.2% from 2019 to 2026.

Biomarker is a biological marker, which indicates a substance or a physical event. These indicated substances or events can be measured and the measurements can be further used for the detection of diseases, a physiological change, response to a treatment and a psychological condition. Biomarker technologies are different techniques, which are employed for testing various diseases. These technologies employ the use of different products to measure a biomarker. Reagents and assays are used in various biomarker technologies such as next generation sequencing, polymerase chain reaction, and others. These biomarker technologies are used in various fields of science such as drug discovery, diagnostics, and personalized medicine. Majorly biomarkers are used to detect diseases such as cancer, infectious diseases, autoimmune diseases, neurological disorders, and others.

Rise in prevalence of various diseases such as autoimmune diseases, cancers, and infectious disease boosts the growth of this market. In addition, the rise in research related to drug discovery, increase in healthcare expenditure, and surge in use of personalized medicine are some other factors that contribute toward the growth of this market. The rise in awareness toward the need of early detection of various diseases such as cancers and high growth potential in emerging economies is anticipated to provide lucrative opportunities in the market during the forecast period. However, high initial investment required for biomarker discovery restricts the growth of the biomarker technologies market.

The biomarker technologies market is segmented based on product, technology, application, indication, and region to provide a detailed assessment of the market. Based on product, the market is divided into consumables, and instruments. The consumables segment is further bifurcated into reagents and assays. Based on technology, the market is divided into polymerase chain reaction, next generation sequencing, immunoassays, and others. On the basis of application, the market is classified into drug discovery, diagnostics and personalized medicine. Based on indication, the market is divided into cancer, infectious diseases, autoimmune disorders, cardiovascular disorders, and others. Based on region, the biomarker technologies market size is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA).

- The study provides an in-depth analysis of the global biomarker technologies market along with the current trends and future estimations to elucidate the imminent investment pockets.
- A quantitative analysis from 2018 to 2026 is discussed to enable the stakeholders to capitalize on the prevailing market opportunities.
- In-depth analysis of biomarker technologies such as polymerase chain reaction, next generation sequencing, immunoassay and others is carried out in the report.
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.


By Product
• Consumables
o Assay
o Reagent
• Instruments

By Technology
• Polymerase Chain Reaction (PCR)
• Next Generation Sequencing (NGS)
• Immunoassay
• Others

By Application
• Drug Discovery
• Diagnostics
• Personalized Medicine

By Indication
• Cancer
• Infectious Diseases
• Autoimmune Disorders
• Cardiovascular Disorders
• Others

By Region
North America
o U.S.
o Canada
o Mexico
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
o India
o China
o Japan
o Australia
o South Korea
o Rest of Asia-Pacific
o Brazil
o South Africa
o Rest of LAMEA

• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• F. Hoffmann-La Roche AG
• Illumina, Inc.
• LI-COR, Inc.
• Merck KGAA
• Shimadzu Corporation
• Thermo Fisher Scientific, Inc.

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
• Eurofins Scientific
• Enzo Biochem, Inc.
• EKF Diagnostics Holdings plc
• Myriad Genetics, Inc. (Myriad RBM.).
• Becton, Dickinson and Company

Read the full report:

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

Contact Clare:
US: (339)-368-6001
Intl: +1 339-368-6001

Cision View original content:

SOURCE Reportlinker